Edwards Lifesciences Mike Mussallem To Retire As CEO, Bernard Zovighian Named Successor
Executive Summary
Mussallem’s retirement at age 70 does not come as a surprise to the Street, but analysts expect some headwinds for his successor Bernard Zovighian, who has been heading the firm’s transcatheter mitral and tricuspid valve repair business.
You may also be interested in...
Getting Personal With Edwards’ Mike Mussallem: Hard Work, Giving Back And Changing The Practice Of Medicine
In this new series titled Getting Personal, we talk to new and veteran senior executives about their journeys to corporate leadership, their motivations, passions, and the peaks and valleys of running a medtech company. Medtech Insight sat down with Mike Mussallem, CEO of Edwards Lifesciences, the leading seller of transcatheter aortic valve replacement (TAVR) devices, at the company’s Irvine, CA-based headquarters.
TCT 2022: Edwards Ready To Take On Abbott In Mitral Repair Market With ‘Premium’ Device
Edwards Lifesciences is ramping up US commercialization of its Pascal Precision mitral valve transcatheter edge-to-edge repair device, the first US competitor for Abbott’s MitraClip. The FDA approved Pascal Precision earlier than the company expected, based on results of the CLASP IID trial.
Edwards Invests In Mitral, Tricuspid Solutions As TAVR Growth Exceeds Expectations
Sales of Sapien transcatheter aortic valves grew about 27% year over year in the third quarter of 2019 while revenues from Edwards’ transcatheter mitral and tricuspid therapies grew to almost $10m, led by sales of the Pascal transcatheter mitral repair system in Europe.